[{"address1": "Paasheuvelweg 25", "city": "Amsterdam", "zip": "1105 BP", "country": "Netherlands", "phone": "31 20 240 6000", "website": "https://www.uniqure.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.", "fullTimeEmployees": 480, "companyOfficers": [{"maxAge": 1, "name": "Mr. Matthew Craig Kapusta", "age": 51, "title": "CEO & Executive Director", "yearBorn": 1972, "fiscalYear": 2023, "totalPay": 1017357, "exercisedValue": 0, "unexercisedValue": 96250}, {"maxAge": 1, "name": "Mr. Christian  Klemt", "age": 50, "title": "CFO, Principal Financial Officer & GM of Amsterdam Site", "yearBorn": 1973, "fiscalYear": 2023, "totalPay": 575462, "exercisedValue": 0, "unexercisedValue": 21000}, {"maxAge": 1, "name": "Mr. Pierre  Caloz", "age": 50, "title": "Chief Operating Officer", "yearBorn": 1973, "fiscalYear": 2023, "totalPay": 882587, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Richard  Porter Ph.D.", "age": 55, "title": "Chief Business & Scientific Officer", "yearBorn": 1968, "fiscalYear": 2023, "totalPay": 732169, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Jeannette  Potts J.D., Ph.D.", "age": 61, "title": "Chief Legal & Compliance Officer and Corporate Secretary", "yearBorn": 1962, "fiscalYear": 2023, "totalPay": 635561, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Prof. Hugo  Katus", "title": "Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Tamara  Tugal Ph.D., MBA", "title": "Business Development Director", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Maria E. Cantor", "age": 55, "title": "Chief Corporate Affairs Officer", "yearBorn": 1968, "fiscalYear": 2023, "totalPay": 491122, "exercisedValue": 0, "unexercisedValue": 1087760}, {"maxAge": 1, "name": "Dr. Amin  Abujoub Ph.D.", "title": "Chief Quality Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Walid  Abi-Saab M.D.", "age": 58, "title": "Chief Medical Officer", "yearBorn": 1965, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 4, "boardRisk": 3, "compensationRisk": 6, "shareHolderRightsRisk": 1, "overallRisk": 3, "governanceEpochDate": 1719792000, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 8.91, "open": 9.19, "dayLow": 8.33, "dayHigh": 9.7776, "regularMarketPreviousClose": 8.91, "regularMarketOpen": 9.19, "regularMarketDayLow": 8.33, "regularMarketDayHigh": 9.7776, "beta": 0.965, "forwardPE": -2.5202312, "volume": 4239913, "regularMarketVolume": 4239913, "averageVolume": 2655342, "averageVolume10days": 13390980, "averageDailyVolume10Day": 13390980, "bid": 8.68, "ask": 8.74, "bidSize": 100, "askSize": 200, "marketCap": 423350784, "fiftyTwoWeekLow": 3.73, "fiftyTwoWeekHigh": 11.35, "priceToSalesTrailing12Months": 22.278103, "fiftyDayAverage": 5.0917, "twoHundredDayAverage": 5.77385, "currency": "USD", "enterpriseValue": 410166080, "floatShares": 39924630, "sharesOutstanding": 48549400, "sharesShort": 2590293, "sharesShortPriorMonth": 2968241, "sharesShortPreviousMonthDate": 1717113600, "dateShortInterest": 1719532800, "sharesPercentSharesOut": 0.053400002, "heldPercentInsiders": 0.04348, "heldPercentInstitutions": 0.69683, "shortRatio": 4.39, "shortPercentOfFloat": 0.0539, "impliedSharesOutstanding": 48549400, "bookValue": 3.026, "priceToBook": 2.8816922, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -296868992, "trailingEps": -6.2, "forwardEps": -3.46, "enterpriseToRevenue": 21.584, "enterpriseToEbitda": -1.739, "52WeekChange": -0.18122065, "SandP52WeekChange": 0.24156773, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "QURE", "underlyingSymbol": "QURE", "shortName": "uniQure N.V.", "longName": "uniQure N.V.", "firstTradeDateEpochUtc": 1391610600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "e051aa7b-edc2-3bc7-a8c8-c2e424dc5a80", "messageBoardId": "finmb_171029664", "gmtOffSetMilliseconds": -14400000, "currentPrice": 8.72, "targetHighPrice": 28.0, "targetLowPrice": 6.0, "targetMeanPrice": 18.36, "targetMedianPrice": 18.0, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 11, "totalCash": 555683008, "totalCashPerShare": 11.446, "ebitda": -235840000, "totalDebt": 542497984, "quickRatio": 8.923, "currentRatio": 9.39, "totalRevenue": 19003000, "debtToEquity": 369.665, "revenuePerShare": 0.397, "returnOnAssets": -0.22112, "returnOnEquity": -1.06115, "freeCashflow": -65845752, "operatingCashflow": -128202000, "revenueGrowth": 0.593, "operatingMargins": -6.3715997, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-07-15"}]